Glioma News and Research

RSS

Glioma is a cancer of the brain that begins in glial cells (cells that surround and support nerve cells).

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.

9 Jun 2014

$Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma$

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Nektar Therapeutics announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

2 Jun 2014

Collaborative research effort produces new genetic insights into brainstem glioma

A collaborative effort between Duke Medicine researchers and neurosurgeons and scientists in China has produced new genetic insights into a rare and deadly form of childhood and young adult brain cancer called brainstem glioma.

2 Jun 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.

31 May 2014

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM).

31 May 2014

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.

31 May 2014

TAG-1 induces apoptosis-related gene expression without triggering apoptosis in glioma cells

A recent study reported by Haigang Chang and co-workers from the First Affiliated Hospital of Xinxiang Medical University in China verified the effects of transient axonal glycoprotein-1 (TAG-1) on cell viability and p53, epidermal growth factor receptor (EGFR), and amyloid precursor protein (APP) intracellular C-terminal domain (AICD) expression in U251 glioma cells.

8 May 2014

Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Researchers at the University of Alabama at Birmingham report a genetically engineered herpes simplex viral therapy is safe when used in conjunction with radiation in the treatment of malignant gliomas, one of the most deadly forms of brain cancer.

9 Apr 2014

Researchers identify potential treatment targets for incurable form of pediatric brain cancer

Researchers from the University of Toronto's Department of Laboratory Medicine and Pathobiology (LMP) have defined potential treatment targets for a previously incurable form of pediatric brain cancer called Diffuse Intrinsic Pontine Glioma (DIPG).

8 Apr 2014

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high-grade gliomas (HGGs), which most often occur in the youngest patients.

8 Apr 2014

Researchers use ultrasound to destroy cancerous tissue in brain

Researchers in Zurich, Switzerland have successfully used focused ultrasound for the first time to non-invasively ablate part of a recurrent glioma tumor through a patient's intact skull.

7 Apr 2014

Study establishes innovative approaches to improve vision of young children with brain tumor

Robert Avery, DO, MSCE, of Children's National Health System and colleagues are establishing innovative approaches with technology and medication to improve the vision of young children who have visual pathway glioma, a type of brain tumor.

3 Mar 2014

Chemotherapy following radiation therapy improves survival for adults with brain tumor

Adults with low-grade gliomas, a form of brain tumor, who received a chemotherapy regimen following completion of radiation therapy, lived longer than patients who received radiation therapy alone, according to long-term follow-up results from a National Institutes of Health-supported randomized controlled clinical trial.

6 Feb 2014

Children who received radiation as part of treatment may have lower long-term survival rates, says study

The first comprehensive, large-scale cohort study of the long-term survival of children treated for low-grade gliomas, the most common pediatric brain tumor, finds that almost 90 percent are alive 20 years later and that few die from the tumor as adults.

4 Feb 2014

IDH1 gene mutation determines best treatment for malignant astrocytomas

Astrocytomas are the most common malignant brain tumors. While most patients' tumors prove to be quite aggressive, outcomes overall can vary widely, with some patients surviving for many years.

4 Feb 2014

New American Cancer Society report calls diagnosis of childhood cancer

A new report from the American Cancer Society outlines progress made and -more importantly-challenges that remain in fighting childhood cancer. The report estimates the number of new cancer cases and deaths for children and adolescents in the United States, summarizes the most recent and comprehensive data on cancer incidence, mortality, and survival, and outlines what is known and where answers are still needed for childhood cancers.

31 Jan 2014

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

21 Jan 2014

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

Glioma News and Research

Further Reading

Gene variants that lead to longer telomeres boost brain cancer risk

Nektar reports etirinotecan pegol Phase 2 study results in patients with Avastin-refractory high-grade glioma

Collaborative research effort produces new genetic insights into brainstem glioma

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

TAG-1 induces apoptosis-related gene expression without triggering apoptosis in glioma cells

Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Researchers identify potential treatment targets for incurable form of pediatric brain cancer

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

Researchers use ultrasound to destroy cancerous tissue in brain

Study establishes innovative approaches to improve vision of young children with brain tumor

Chemotherapy following radiation therapy improves survival for adults with brain tumor

Children who received radiation as part of treatment may have lower long-term survival rates, says study

IDH1 gene mutation determines best treatment for malignant astrocytomas

New American Cancer Society report calls diagnosis of childhood cancer

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Experimental drug that targets macrophages decreases cancer's growth

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News